Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Intangibles (2019 - 2025)

Quantum Biopharma's Intangibles history spans 7 years, with the latest figure at $4.5 million for Q4 2025.

  • On a quarterly basis, Intangibles fell 8.53% to $4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.5 million, a 8.53% decrease, with the full-year FY2025 number at $4.5 million, down 8.53% from a year prior.
  • Intangibles hit $4.5 million in Q4 2025 for Quantum Biopharma, down from $4.6 million in the prior quarter.
  • Over the last five years, Intangibles for QNTM hit a ceiling of $17.3 million in Q3 2021 and a floor of $4.5 million in Q4 2025.
  • Historically, Intangibles has averaged $9.4 million across 5 years, with a median of $8.0 million in 2023.
  • Biggest five-year swings in Intangibles: increased 20.51% in 2021 and later plummeted 60.98% in 2023.
  • Tracing QNTM's Intangibles over 5 years: stood at $16.2 million in 2021, then dropped by 25.69% to $12.0 million in 2022, then tumbled by 54.64% to $5.5 million in 2023, then dropped by 9.66% to $4.9 million in 2024, then fell by 8.53% to $4.5 million in 2025.
  • Business Quant data shows Intangibles for QNTM at $4.5 million in Q4 2025, $4.6 million in Q3 2025, and $4.7 million in Q2 2025.